Posted 3/15/2023
Severe forms of neurofibromatosis linked to disruptions in a protein partnership New research by Frederick National...
Posted 2/15/2023
To celebrate International Women and Girls in Science Day, we co-hosted a panel discussion on Feb. 10 with Woman to...
Posted 11/15/2022
The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer...
All News
Untangling the complex genetics of neurofibromatosis
Protein Expression Laboratory, Advanced Cryo-Electron Microscopy Technology GroupPosted 3/15/2023Severe forms of neurofibromatosis linked to disruptions in a protein partnership
New research by Frederick National Laboratory (FNL) researchers and their colleagues takes an important step toward explaining complex mutations in a gene called NF1 that is known to cause a disorder known as neurofibromatosis type 1. The study also has potential implications in research…
Trends observed in nearly 20 years of nanotech data offer insight
Nanotechnology Characterization LaboratoryPosted 3/7/2023Scientists at Frederick National Laboratory for Cancer Research and the National Cancer Institute have analyzed nearly two decades’ worth of data about biomedical nanotechnology studies, revealing patterns never seen before.
While that may seem exclusively like the domain of laboratory coats and computers, removed from the realm of public concern, its appearance belies…
Women pursuing science add value to the endeavor, with support from mentors and allies
Posted 2/15/2023
To celebrate International Women and Girls in Science Day, we co-hosted a panel discussion on Feb. 10 with Woman to Woman Mentoring and Hood College where successful women in science discussed their chosen career paths, allyship and mentorship in science and strategies for advancement. This was the second annual Women in Science event and the first in-person.
Women…
Looking Back, Looking Ahead: 2022’s AI Symposium Charted Paths for Cancer Research Progress
Bioinformatics and Computational Science, Cancer Data Science InitiativesPosted 2/2/2023
Last year, some of the world’s top leaders in the field came together to discuss the progress of artificial intelligence (AI) applications in cancer research and clinical care at a scientific symposium hosted by Hood College and Frederick National Laboratory (FNL).
It was one of several large scientific gatherings in Frederick in 2022 with implications for the new year…
Encephalitis vaccine does well in early clinical trial; commercial development pending
Vaccine Clinical Materials ProgramPosted 12/21/2022Commercial development of a vaccine against three types of mosquito-borne equine encephalitis viruses — which are classified as potential biological warfare agents and can be fatal in humans — has begun following a government-led phase I clinical trial conducted with materials produced by the Frederick National Laboratory’s Vaccine Clinical Materials Program.
No therapies…
Partnership trainees embrace opportunity for hands-on experience and opt for extended time in FNL laboratories
Partnership Development OfficePosted 12/19/2022Undergraduate and graduate students from academic institutions that partner with the Frederick National Laboratory for Cancer Research gained laboratory experience through the Partnership Trainee Program 2022 summer session, which this year added the Morehouse School of Medicine and the program’s first medical student trainee.
“By welcoming our first medical student, we…
Frederick National Laboratory produces CAR T-cell immunotherapies for pediatric cancer clinical trials
Biopharmaceutical Development ProgramPosted 11/15/2022
The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer-killers that are being used to treat children and young adults participating in early-phase pediatric cancer trials.
The treatment is called chimeric antigen receptor (CAR) T cell therapy. CAR T cells are a type of white blood cell that has been removed…
Real-world studies indicate NSAIDs improve lung cancer survival
Ethan Dmitrovsky, M.D.Posted 11/8/2022Common drugs for controlling pain and inflammation – such as aspirin and ibuprofen – improved overall lung cancer survival by a statistically significant margin in a long-term study of patient medical records. This finding called for more definitive randomized clinical trials.
Use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a survival rate of 29.7…
Renowned FNL scientist joins late father-in-law and world leaders as member of American Academy of Arts and Sciences
Basic Science ProgramPosted 11/2/2022
Upon hearing earlier this year that she was elected to the prestigious American Academy of Arts and Sciences, cancer scientist Mary Carrington wished she could share the news with her beloved late father-in-law, a former law school dean at Duke.
She had only discovered Paul Carrington’s academy membership after he died last year, when she and her husband found the…
Annual Technology Showcase to spotlight collaboration opportunities with NCI and FNL
Partnership Development OfficePosted 8/18/2022
The National Cancer Institute and Frederick National Laboratory for Cancer Research will hold the annual Technology Showcase on Wednesday, Sept. 7 in a hybrid format to welcome in-person attendees as well as remote participants from around the United States and the world. The event is scheduled from noon to 5:30 pm ET at the FNL’s Advanced Technology Research Facility in…
Media Inquiries
For all media related questions please contact:
Mary Ellen Hackett
Manager, Communications Office